icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Significant Improvements in MRI-PDFF in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH
  Reported by Jules Levin
AASLD: The Liver Meeting 2017, October 20-24, 2017, Washington, DC
Rohit Loomba,1 Zeid Kayali,2 Mazen Noureddin,3 Peter Ruane,4 Eric J. Lawitz,5 Norman Gitlin,6 Michael Bennett,7 ElizaJing Harting,8 Bryan J. McColgan,8 Robert P. Myers,8 G. Mani Subramanian,8 John G. McHutchison,8 Michael S. Middleton,1 Claude Sirlin,1 Michelle Lai,9 Michael Charlton,10
Stephen A. Harrison11
1University of California at San Diego, La Jolla, CA; 2. Inland Empire Liver Foundation, Rialto, CA; 3. Cedars-Sinai Medical Center, Los Angeles, CA; 4. Ruane Medical and Liver Health Institute, Los Angeles, CA; 5. Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX; 6. Atlanta Gastroenterology Associates, Atlanta, GA; 7. Medical Research Associates Group, San Diego, CA; 8. Gilead Sciences, Inc., Foster City, CA; 9. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; 10. University of Chicago, Chicago, IL; 11. Pinnacle Clinical Research, San Antonio, TX